RNAi-based Therapeutics Targeting Survivin and PLK1 for Treatment of Bladder Cancer
Open Access
- 1 May 2011
- journal article
- Published by Elsevier BV in Molecular Therapy
- Vol. 19 (5), 928-935
- https://doi.org/10.1038/mt.2011.21
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Improved specificity of gene silencing by siRNAs containing unlocked nucleobase analogsNucleic Acids Research, 2010
- Analysis of acyclic nucleoside modifications in siRNAs finds sensitivity at position 1 that is restored by 5′-terminal phosphorylation both in vitro and in vivoNucleic Acids Research, 2009
- Intravesical Treatments of Bladder Cancer: ReviewPharmaceutical Research, 2008
- Sequence- and target-independent angiogenesis suppression by siRNA via TLR3Nature, 2008
- Targeting survivin in cancer therapyEmerging Therapeutic Targets, 2008
- Cell type–dependent effects of Polo-like kinase 1 inhibition compared with targeted polo box interference in cancer cell linesMolecular Cancer Therapeutics, 2007
- A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imagingBJU International, 2007
- Polo-like kinases and the orchestration of cell divisionNature Reviews Molecular Cell Biology, 2004
- Effect of Intravesical Treatment of Transitional Cell Carcinoma With Bacillus Calmette-Guerin and Mitomycin C on Urinary Survivin Levels and OutcomeJournal of Urology, 2003
- Bladder cancer detection with urinary survivin, an inhibitor of apoptosisFrontiers in Bioscience-Landmark, 2002